3,344,519 results match your criteria Oncology Times UK Edition [Journal]


New Insights into Long Non-Coding RNA in Cancer and Metastasis.

Authors:
Yutong Sun Li Ma

Cancers (Basel) 2019 Feb 13;11(2). Epub 2019 Feb 13.

Department of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Metastasis-associated lung adenocarcinoma transcript 1 () is one of the most abundant, long non-coding RNAs (lncRNAs) in normal tissues. This lncRNA is highly conserved among mammalian species, and based on in vitro results, has been reported to regulate alternative pre-mRNA splicing and gene expression. However, knockout mice develop and grow normally, and do not show alterations in alternative splicing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020216DOI Listing
February 2019

Phosphorus Concentration in Knee Joint Structures of Patients Following Replacement Surgery.

Int J Environ Res Public Health 2019 Feb 13;16(4). Epub 2019 Feb 13.

Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University in Szczecin, Żołnierska 54, 71-210 Szczecin, Poland.

The aim of the study was to assess phosphorus (P) concentration in structures of the knee joint-including the tibial spongy bone, articular cartilage, meniscus, anterior cruciate ligament, and infrapatellar fat pad (Hoffa's fat pad)-of patients following knee joint replacement. The study also aimed to assess the influence of selected biological and environmental factors on P concentration in studied parts of the knee joint. Phosphorus concentration was determined using inductively coupled plasma-atomic emission spectrometry (ICP-AES). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph16040525DOI Listing
February 2019

High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO₂-Au Nanocomposite.

Molecules 2019 Feb 13;24(4). Epub 2019 Feb 13.

School of Basic Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou 450002, Henan, China.

Progastrin-releasing peptide (ProGRP), which is known to be highly specific and sensitive to small cell lung cancer (SCLC), has been proven to be a valuable substitute for neuron-specific enolase in SCLC diagnostics and monitoring, especially in its early stages. The detection of ProGRP levels also facilitates a selection of therapeutic treatments. For the fabrication of our proposed biosensor, titanium (IV) oxide microparticles were first used, followed by dispersing gold nanoparticles into chitosan and immobilizing them onto a carbon paste electrode (CPE) surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24040656DOI Listing
February 2019

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.

Cancers (Basel) 2019 Feb 18;11(2). Epub 2019 Feb 18.

Department of Gynecology and Obstetrics, University Hospital of Essen, 45122 Essen, Germany.

Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an "all from one tube" format is desired. We investigated whether cfDNA variant sequencing from CTC-depleted blood (CTC-depl. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020238DOI Listing
February 2019

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Cancers (Basel) 2019 Feb 18;11(2). Epub 2019 Feb 18.

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020236DOI Listing
February 2019

Leukocyte⁻Cancer Cell Fusion-Genesis of a Deadly Journey.

Cells 2019 Feb 18;8(2). Epub 2019 Feb 18.

Department of Dermatology and The Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8059, USA.

According to estimates from the International Agency for Research on Cancer, by the year 2030 there will be 22 million new cancer cases and 13 million deaths per year. The main cause of cancer mortality is not the primary tumor itself but metastasis to distant organs and tissues, yet the mechanisms of this process remain poorly understood. Leukocyte⁻cancer cell fusion and hybrid formation as an initiator of metastasis was proposed more than a century ago by the German pathologist Prof. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8020170DOI Listing
February 2019

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer.

J Clin Med 2019 Feb 18;8(2). Epub 2019 Feb 18.

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.

Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8020254DOI Listing
February 2019

CVm6A: A Visualization and Exploration Database for m⁶As in Cell Lines.

Cells 2019 Feb 17;8(2). Epub 2019 Feb 17.

School of Basic Medical Sciences, Wuhan University, Wuhan 430071, Hubei, China.

N6-methyladenosine (m⁶A) has been identified in various biological processes and plays important regulatory functions in diverse cells. However, there is still no visualization database for exploring global m⁶A patterns across cell lines. Here we collected all available MeRIP-Seq and m⁶A-CLIP-Seq datasets from public databases and identified 340,950 and 179,201 m⁶A peaks dependent on 23 human and eight mouse cell lines respectively. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2073-4409/8/2/168
Publisher Site
http://dx.doi.org/10.3390/cells8020168DOI Listing
February 2019
1 Read

Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential.

Int J Mol Sci 2019 Feb 16;20(4). Epub 2019 Feb 16.

Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China.

MicroRNA-34a (miR-34a), a tumor suppressor, has been reported to be dysregulated in various human cancers. MiR-34a is involves in certain epithelial-mesenchymal transition (EMT)-associated signal pathways to repress tumorigenesis, cancer progression, and metastasis. Due to the particularity of miR-34 family in tumor-associated EMT, the significance of miR-34a is being increasingly recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040861DOI Listing
February 2019

Exploring lncRNA-Mediated Regulatory Networks in Endometrial Cancer Cells and the Tumor Microenvironment: Advances and Challenges.

Cancers (Basel) 2019 Feb 16;11(2). Epub 2019 Feb 16.

Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.

Recent studies have revealed both the promise and challenges of targeting long non-coding RNAs (lncRNAs) to diagnose and treat endometrial cancer (EC). LncRNAs are upregulated or downregulated in ECs compared to normal tissues and their dysregulation has been linked to tumor grade, FIGO stage, the depth of myometrial invasion, lymph node metastasis and patient survival. Tumor suppressive lncRNAs (GAS5, MEG3, FER1L4 and LINC00672) and oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, H19 and Linc-RoR) have been identified as upstream modulators or downstream effectors of major signaling pathways influencing EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin and p53 signaling pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020234DOI Listing
February 2019

Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases.

Cancers (Basel) 2019 Feb 16;11(2). Epub 2019 Feb 16.

Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

Diagnosis-specific survival scores including a new score developed in 157 patients with brain metastases from small-cell lung cancer (SCLC) receiving whole-brain radiotherapy (WBRT) with 30 Gy in 10 fractions (WBRT-30-SCLC) were compared. Three prognostic groups were designed based on the 6-month survival probabilities of significant or almost significant factors, (age, performance score, number of brain metastases, extra-cerebral metastasis). Six-month survival rates were 6% (6⁻11 points), 44% (12⁻14 points) and 86% (16⁻19 points). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020233DOI Listing
February 2019

Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia.

Medicina (Kaunas) 2019 Feb 16;55(2). Epub 2019 Feb 16.

Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.

Recent studies suggest that a vascular endothelial growth factor (VEGF-A) may be involved in the thrombotic process by stimulating the expression of tissue factor in vascular endothelial cells. Tissue factor (TF) can also stimulate the transcription of the gene encoding VEGF-A. The relationship between coagulation and angiogenesis in myeloproliferative neoplasms is not fully understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina55020054DOI Listing
February 2019

Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer.

Cells 2019 Feb 16;8(2). Epub 2019 Feb 16.

Department of Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

Histone ubiquitination is a critical epigenetic mechanism regulating DNA-driven processes such as gene transcription and DNA damage repair. Importantly, the cellular machinery regulating histone ubiquitination is frequently altered in cancers. Moreover, aberrant histone ubiquitination can drive oncogenesis by altering the expression of tumor suppressors and oncogenes, misregulating cellular differentiation and promoting cancer cell proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8020165DOI Listing
February 2019

Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance.

Int J Mol Sci 2019 Feb 16;20(4). Epub 2019 Feb 16.

Laboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy.

The unfolded protein response (UPR) is a stress response activated by the accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum (ER) and its uncontrolled activation is mechanistically responsible for several human pathologies, including metabolic, neurodegenerative, and inflammatory diseases, and cancer. Indeed, ER stress and the downstream UPR activation lead to changes in the levels and activities of key regulators of cell survival and autophagy and this is physiologically finalized to restore metabolic homeostasis with the integration of pro-death or/and pro-survival signals. By contrast, the chronic activation of UPR in cancer cells is widely considered a mechanism of tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040857DOI Listing
February 2019

-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity.

Int J Mol Sci 2019 Feb 15;20(4). Epub 2019 Feb 15.

Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia.

Six new organotin(IV) compounds of Schiff bases derived from -R-dithiocarbazate [R = benzyl (B), 2- or 4-methylbenzyl (2M and 4M, respectively)] condensed with 2-hydroxy-3-methoxybenzaldehyde (oVa) were synthesised and characterised by elemental analysis, various spectroscopic techniques including infrared, UV-vis, multinuclear (¹H, C, Sn) NMR and mass spectrometry, and single crystal X-ray diffraction. The organotin(IV) compounds were synthesised from the reaction of Ph₂SnCl₂ or Me₂SnCl₂ with the Schiff bases (S2MoVaH/S4MoVaH/SBoVaH) to form a total of six new organotin(IV) compounds that had a general formula of [R₂Sn(L)] (where L = Schiff base; R = Ph or Me). The molecular geometries of Me₂Sn(S2MoVa), Me₂Sn(S4MoVa) and Me₂Sn(SBoVa) were established by X-ray crystallography and verified using density functional theory calculations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040854DOI Listing
February 2019

2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, F-Labeling and Preclinical PET Imaging.

Pharmaceuticals (Basel) 2019 Feb 15;12(1). Epub 2019 Feb 15.

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany.

The benefits of PET imaging of tumor hypoxia in patient management has been demonstrated in many examples and with various tracers over the last years. Although, the optimal hypoxia imaging agent has yet to be found, 2-nitroimidazole (azomycin) sugar derivatives-mimicking nucleosides-have proven their potential with [F]FAZA ([F]fluoro-azomycin--arabinoside) as a prominent representative in clinical use. Still, for all of these tracers, cellular uptake by passive diffusion is postulated with the disadvantage of slow kinetics and low tumor-to-background ratios. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph12010031DOI Listing
February 2019

Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma.

Cancers (Basel) 2019 Feb 15;11(2). Epub 2019 Feb 15.

Department of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.

Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a large heterogeneity in terms of the location and risk factors. For a few years now, immunotherapy seems to be a promising approach in the treatment of these cancers, but a better understanding of the immune context could allow to offer a personalized treatment and thus probably increase the survival of HNSCC patients. In this context, we evaluated the infiltration of FoxP3+ Tregs on 205 human formalin-fixed paraffin-embedded HNSCC and we assessed its prognostic value compared to other potential prognostic factors, including HPV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020227DOI Listing
February 2019

Detecting Chromosome Instability in Cancer: Approaches to Resolve Cell-to-Cell Heterogeneity.

Cancers (Basel) 2019 Feb 15;11(2). Epub 2019 Feb 15.

Department of Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

Chromosome instability (CIN) is defined as an increased rate of chromosome gains and losses that manifests as cell-to-cell karyotypic heterogeneity and drives cancer initiation and evolution. Current research efforts are aimed at identifying the etiological origins of CIN, establishing its roles in cancer pathogenesis, understanding its implications for patient prognosis, and developing novel therapeutics that are capable of exploiting CIN. Thus, the ability to accurately identify and evaluate CIN is critical within both research and clinical settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020226DOI Listing
February 2019

Combining many-objective radiomics and 3-dimensional convolutional neural network through evidential reasoning to predict lymph node metastasis in head and neck cancer.

Phys Med Biol 2019 Feb 19. Epub 2019 Feb 19.

Department of Radiation Oncology, University of Texas Southwestern Medical Centre, 5801 Forest Park Road, Dallas, TX 75390-9183, Dallas, Texas, UNITED STATES.

Lymph node metastasis (LNM) is a significant prognostic factor in patients with head and neck cancer, and the ability to predict it accurately is essential to optimizing treatment. Positron emission tomography (PET) and computed tomography (CT) imaging are routinely used to identify LNM. Although large or highly active lymph nodes (LNs) have a high probability of being positive, identifying small or less reactive LNs is challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/ab083aDOI Listing
February 2019

Seizure and epilepsy publication in nonneurology journals.

Epilepsy Behav 2019 Feb 16;93:7-11. Epub 2019 Feb 16.

Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America; Minnesota Epilepsy Group, P.A., St. Paul, MN, United States of America.

Purpose: The prevalence and characteristics of seizure and epilepsy research published in nonneurology journals are unknown. Characterizing this published research allows for insight into the relevance of seizures and epilepsy in other specialties and may increase opportunity for cross-specialty collaboration.

Methods: In this observational study, we reviewed the top five highly cited clinical journals within eleven specialties in the InCites Journal Citation Reports (JCR) database (2016). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2019.01.032DOI Listing
February 2019

Spontaneous Subdural Hematoma in a Patient with Polycythemia Vera.

World Neurosurg 2019 Feb 16. Epub 2019 Feb 16.

Department of Neurosurgery, Albany Medical Center, Albany, NY, USA.

Polycythemia vera (PV) is a myeloproliferative disorder usually characterized by an increase tendency towards thromboembolic events. Spontaneous hemorrhage/bleeding in PV patients is seldom reported in Neurosurgical literature. We report the case of a 76 year-old male with PV who developed a spontaneous subdural hematoma requiring surgical evacuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.01.258DOI Listing
February 2019

Chronic myeloid leukemia: Two mysteries.

Leuk Res 2019 Feb 12;79:3-5. Epub 2019 Feb 12.

Haematology Research Centre, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.003DOI Listing
February 2019

Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis.

Thromb Res 2019 Feb 13;176:79-84. Epub 2019 Feb 13.

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.

Background: Unprovoked venous thromboembolism (VTE) may be the first manifestation of an underlying cancer. We aimed to assess the period prevalence of occult cancer detection stratified by VTE location (deep vein thrombosis [DVT], pulmonary embolism [PE] or both) and the anatomical relationship between occult cancer and VTE.

Methods: Post-hoc analysis of a systematic review and individual patient data meta-analysis of adults with unprovoked VTE with at least 12 months of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2019.02.011DOI Listing
February 2019

Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of medical oncology, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Paris-Sud University, Orsay, France.

Introduction: although frequent in non-small cell lung cancer (NSCLC), brain metastases (BM) patients are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less selected NSCLC cohort.

Methods: data from consecutive advanced ICI treated NSCLC patients were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.009DOI Listing
February 2019

PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of Thoracic / Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0432, Houston, Texas, 77030, United States of America. Electronic address:

Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of non-small cell lung cancer (NSCLC), but only ∼15% of patients achieve durable benefit. Understanding resistance mechanisms to ICB is pivotal in developing more effective treatment strategies. Recent studies showed human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.008DOI Listing
February 2019

Human primary macrophages scavenge aunps and eliminate it through exosomes. a natural shuttling for nanomaterials.

Eur J Pharm Biopharm 2019 Feb 16. Epub 2019 Feb 16.

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Electronic address:

The use of nanomaterials is increasing but the real risk associated with their use in humans has to be defined. In fact, nanomaterials tend to accumulate in organs over a long period of time and are slowly degraded or eliminated by the body. Exosomes are nanovesicles actively shuttle molecules, including chemical products and metals, through the body. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2019.02.014DOI Listing
February 2019

A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.

Gene 2019 Feb 16. Epub 2019 Feb 16.

Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China. Electronic address:

Background: The microRNAs (miRNAs) have been validated as prognostic markers in many cancers. The aim of this study was to identify new miRNA prognostic biomarkers in endometrial cancer (EC) and to develop an expression-based miRNA signature to provide survival risk prediction for EC patients.

Methods: From TCGA database, the miRNA datasets of EC and clinical information were downloaded in April 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2019.01.046DOI Listing
February 2019

MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice.

Gastroenterology 2019 Feb 16. Epub 2019 Feb 16.

State Key Laboratories for Agrobiotechnology and Beijing Advanced Innovation Center for Food Nutrition and Human Health and, College of Biological Sciences, China Agricultural University, Beijing, China. Electronic address:

Background & Aims: Levels of microRNA 31 (MIR31) are increased in intestinal tissues from patients with inflammatory bowel diseases and colitis-associated neoplasias. We investigated the effects of this microRNA on intestinal inflammation by studying mice with colitis.

Methods: We obtained colon biopsy samples from 82 patients with ulcerative colitis (UC), 79 patients with Crohn's disease (CD), and 34 healthy individuals (controls) at Shanghai Tenth People's Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.02.023DOI Listing
February 2019

miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1.

Exp Cell Res 2019 Feb 16. Epub 2019 Feb 16.

Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China 2. Electronic address:

Paclitaxel (Taxol) is an anticancer taxane drug commonly used in the treatment of nasopharyngeal carcinoma (NPC). However, resistance to paclitaxel is a major difficulty in developing an effective therapy against NPC. MicroRNAs (miRNAs) are known to regulate genes that are involved in drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.02.012DOI Listing
February 2019

Prediction of lymph node metastasis in oral squamous cell carcinoma based on protein profile.

Expert Rev Proteomics 2019 Feb 19. Epub 2019 Feb 19.

a Department of Oral and Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital & College of Stomatology , Shanghai Jiao Tong University School of Medicine ; Shanghai 200011 , China.

Objective: Lymph node metastasis leads to high mortality rates of oral squamous cell carcinoma (OSCC). However, it is still controversial to define clinically negative neck (cN0) and positive neck (cN1-3).

Methods: We retrieved candidate biomarkers identified by proteomic analysis in OSCC from published literatures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2019.1584039DOI Listing
February 2019

Comparison of outcomes of free-hand 2-dimensional ultrasound-guided versus navigated 3-dimensional ultrasound-guided biopsy for supratentorial tumours: a single-institution experience with 125 cases.

Ultrasonography 2018 Dec 8. Epub 2018 Dec 8.

Division of Neurosurgery, Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Purpose: The purpose of this study was to evaluate the relative utility and benefits of free-hand 2-dimensional intraoperative ultrasound (FUS) and navigated 3-dimensional intraoperative ultrasound (NUS) as ultrasound-guided biopsy (USGB) techniques for supratentorial lesions.

Methods: All patients who underwent USGB for suspected supratentorial tumours from January 2008 to December 2017 were retrospectively analyzed. The charts and electronic medical records of these patients were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14366/usg.18036DOI Listing
December 2018

Non-neuroendocrine neoplasms of the pituitary region.

J Clin Endocrinol Metab 2019 Feb 19. Epub 2019 Feb 19.

Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom.

Context: Although the majority of sellar lesions are related to pituitary adenomas, the region gives rise to a variety of neoplasms that can be associated with substantial morbidity and/or mortality.

Evidence Acquisition: Information from reviews and guidelines of relevant societies dealing with such neoplasms, and articles that have provided new developments which made important contributions in their pathogenesis and treatment up to 2018, were obtained: public indexes such as PubMed/MEDLINE were used with the search items.

Evidence Synthesis: Sellar neoplasms have a worse outcome than pituitary adenomas that is related not only to their natural history but also to side effects of therapies and evolving endocrine and/or hypothalamic deficiencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-01871DOI Listing
February 2019

Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma.

J Clin Endocrinol Metab 2019 Feb 19. Epub 2019 Feb 19.

Department of Endocrinology and Metabolism, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (USP), São Paulo, Brazil.

Context: Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report the first case of acquired generalized lipodystrophy possibly associated with nivolumab.

Case Description: A woman was referred to our Endocrinology Department for uncontrolled diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02221DOI Listing
February 2019

Epstein-Barr virus-associated gastric ulcer mimicking gastric neoplasia: a case report.

Med Ultrason 2019 Feb;21(1):96-98

Department of Gastroenterology, Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj-Napoca, Romania.

We describe a rare case of a severe gastric ulcer of a 66-year-old immunocompetent man who was associated with primary Epstein-Barr virus (EBV) infection and temporarily misdiagnosed with gastric lymphoma. A contrast-enhanced computed tomography (CT-scan) of the thorax, abdomen and pelvis followed by EUS revealed a neoplastic infiltrative-ulcerative semicircumferentialgastric mass and a 1 cm large satellite adenopathy, being classified as T3N1M0 gastric neoplasia. The histological analysis of the ¾ distal stomach and lymph node sthat were resected contradicted the initial biopsy report, suggesting EBV gastric ulcer, etiology confirmed by the in situ hybridization technique. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11152/mu-1560DOI Listing
February 2019

Clinical management of localized undifferentiated sinonasal carcinoma: our experience and review of the literature.

Anticancer Drugs 2019 Mar;30(3):308-312

Departments of Head and Neck and Sarcoma Oncology.

Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000707DOI Listing

Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC.

JCI Insight 2019 Feb 19. Epub 2019 Feb 19.

Glioblastoma represent universally lethal cancers, containing stem cell-like glioblastoma stem cells (GSCs). While neural stem cells (NSCs) are usually quiescent, single-cell studies suggest that proliferating glioblastoma cells reside in the GSC population. Interrogating in silico glioma databases for epigenetic regulators that correlate with cell cycle regulation, we identified the chromatin remodeler, HELLS, as a potential target in glioblastoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.126140DOI Listing
February 2019

Management of Cardiovascular Disease in Women With Breast Cancer.

Circulation 2019 Feb;139(8):1110-1120

Division of Cardiology, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Georgetown University, Washington, DC (A.B.).

Cardio-oncology is a rapidly developing field which seeks to improve patient outcomes through enhanced clinical and research collaboration across the disciplines of oncology and cardiology. Breast cancer (BC) is the most common cancer diagnosis among women in the United States and, as decades of research have resulted in decreased mortality rates, there has been an increasing focus on reducing short- and long-term treatment toxicity and improving morbidity among survivors. Preexisting or emergent cardiovascular disease in a patient with BC requires a multidisciplinary, team-based approach to balance the need for curative cancer treatment while preventing increased cardiovascular disease morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039371DOI Listing
February 2019

IL-6 released from muscles during exercise is stimulated by lactate-dependent protease activity.

Am J Physiol Endocrinol Metab 2019 Feb 19. Epub 2019 Feb 19.

The Centre of Inflammation and Metabolism (CIM) and the Centre for Physical Activity Research (CFAS), Copenhagen University Hospital, 7641, University of Copenhagen, Denmark.

Background: IL-6 is secreted from muscles to the circulation during high intensity and long duration exercise, where muscle-derived IL-6 works as an energy sensor to increase release of energy substrates from liver and adipose tissues. Here, we investigated the mechanism involved in the exercise-mediated surge in IL-6 during exercise.

Methods: Using interval-based cycling in healthy young men, swimming exercise in mice and electrical stimulation of primary human muscle cells, we explored the role of lactate production in muscular IL-6 release during exercise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpendo.00414.2018DOI Listing
February 2019

The Special Pathogens Research Network: Enabling Research Readiness.

Health Secur 2019 Jan/Feb;17(1):35-45

Christopher J. Kratochvil, MD, is Associate Vice Chancellor for Clinical Research, the University of Nebraska Medical Center, Omaha, NE.

The 2013-2016 epidemic of Ebola virus disease (EVD) that originated in West Africa underscored many of the challenges to conducting clinical research during an ongoing infectious disease epidemic, both in the most affected countries of Guinea, Liberia, and Sierra Leone, as well as in the United States and Europe, where a total of 27 patients with EVD received care in biocontainment units. The Special Pathogens Research Network (SPRN) was established in the United States in November 2016 to provide an organizational structure to leverage the expertise of the 10 Regional Ebola and Other Special Pathogen Treatment Centers (RESPTCs); it was intended to develop and support infrastructure to improve readiness to conduct clinical research in the United States. The network enables the rapid activation and coordination of clinical research in the event of an epidemic and facilitates opportunities for multicenter research when the RESPTCs are actively caring for patients requiring a biocontainment unit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/hs.2018.0106DOI Listing
February 2019

Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.

J Glob Oncol 2019 Feb(5):1-8

1 Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.

Purpose: Reported treatment outcomes for patients with advanced germ cell tumors (aGCT) are based mainly on series from developed nations. Data from low- and middle-income countries are underrepresented.

Material And Methods: From 2000 to 2015, a retrospective analysis identified 300 patients with aGCT treated at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.18.00170DOI Listing
February 2019

Role of Close Endocervical Margin in Treatment Failure After Cervical Excision for Cervical Intraepithelial Neoplasia: A Retrospective Study.

Arch Pathol Lab Med 2019 Feb 19. Epub 2019 Feb 19.

From the Gynecological Oncology Unit (Drs Sopracordevole and del Fabro and Ms Buttignol).

Context.—: A significant negative trend in length of cone excision has been observed in recent years, leading to a higher percentage of positive endocervical excision margin and close (<1 mm) negative endocervical margin.

Objective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0363-OADOI Listing
February 2019

High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling.

Arch Pathol Lab Med 2019 Feb 19. Epub 2019 Feb 19.

From the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston.

High-grade sinonasal carcinomas are a cohort of malignant epithelial neoplasms arising in the sinonasal cavities with distinct, ominous morphologic features or lacking well-differentiated features that might otherwise classify them as less biologically worrisome. Recent advances in molecular profiling have led to the identification of several distinct tumor entities previously grouped together. These molecularly distinct lesions include NUT (midline) carcinoma, INI1 ( SMARCB1)-deficient carcinoma, SMARCA4-deficient sinonasal carcinoma, and novel IDH-mutant sinonasal undifferentiated carcinoma, in addition to the previously described lymphoepithelial carcinoma that may also be included in the differential diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0224-RSDOI Listing
February 2019

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital-Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) - all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) - both in France; the University of Texas M.D. Anderson Cancer Center, Houston (M.T.C.); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow (B.V.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; British Columbia Cancer Agency, Vancouver (C.K.), and Lady Davis Institute and Jewish General Hospital, McGill University, Montreal (W.H.M.) - both in Canada; Osaka University Hospital, Osaka, Japan (M.U.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.L.L.); Macquarie University, Sydney (H.G.); Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna (M.S.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.); Department of Urology, University of Tübingen, Tübingen, Germany (J.B.); Pfizer, Cambridge (J.W., A.C.), and the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston (T.K.C.) - both in Massachusetts; Pfizer (M.M., A.P.) and Pfizer Italia (C.F.), Milan; Pfizer, San Diego, CA (P.B.R.); and Pfizer, Groton, CT (B.H.).

Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib.

Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816047DOI Listing
February 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

Background: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.

Methods: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
February 2019

Implementation of High Dose-rate Brachytherapy for Cervix Cancer in a Low-income Country.

Ann Glob Health 2018 Nov 5;84(4):679-682. Epub 2018 Nov 5.

Department of Radiation Oncology, University of Florida, US.

Background: The purpose of this study is to detail the implementation of HDR brachytherapy at the only radiotherapy center in Nicaragua.

Methods: Patients are treated with external-beam radiotherapy to 46-50Gy at 2Gy/fraction to the pelvis. A gynecologic examination is performed weekly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.9204/aogh.2377DOI Listing
November 2018

[UNUSUAL VITREOUS DETACHMENT].

Harefuah 2019 Feb;158(2):109-111

Ocular Oncology Service - The Goldschleger Eye Institute, Sheba Medical Center, Tel-Aviv University, Israel.

Introduction: A 49 years old patient with a history of brachytherapy for choroidal melanoma was referred to the ocular emergency room for suspected recurrence due to pigment in the vitreous cavity. On examination, pigmented vitreous secondary to posterior vitreous detachment with traction from the atrophic tumor was observed with no evidence of recurrence. Read More

View Article

Download full-text PDF

Source
February 2019

HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease: A multicentre study.

Int J Immunogenet 2019 Feb 19. Epub 2019 Feb 19.

Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary.

Background And Purpose: Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes.

Methods: We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iji.12415DOI Listing
February 2019

Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults.

J Clin Lab Anal 2019 Feb 19:e22863. Epub 2019 Feb 19.

Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.

Background: Neuron-specific enolase (NSE) is an important tumor marker in the serum of patients with lung cancer. Elevated serum NSE levels are also associated with many other diseases. However, there is no unified population reference interval for serum NSE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcla.22863DOI Listing
February 2019

Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer.

Head Neck 2019 Feb 19. Epub 2019 Feb 19.

Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio.

Background: To report our institutional experience with intraoperative radiotherapy for persistent or recurrent head and neck cancer.

Methods: Sixty-one patients were treated with salvage surgery and intraoperative radiation therapy (IORT). Fifty-eight patients (95%) had previously received external beam radiotherapy (EBRT) as a component of their definitive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25673DOI Listing
February 2019

Radiotherapy for benign head and neck paragangliomas.

Head Neck 2019 Feb 19. Epub 2019 Feb 19.

Department of Otolaryngology, University of Florida College of Medicine, Gainesville, Florida.

Purpose: To update our experience treating benign head-and-neck paragangliomas (PGs) with radiotherapy (RT).

Methods: A total of 149 patients with 176 PGs received curative-intent RT; 126 received RT to 1 PG and 23 to 2 or more PGs. The most common dose fractionation schedule was 45 Gy/25 once-daily fractions/5 weeks which was used to treat 147 PGs (83. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25664DOI Listing
February 2019
  • Page 1 of 66891